稳健医疗用品股份有限公司 2024 年度独立董事述职报告 （彭剑锋） 各位股东及股东代表： 作为稳健医疗用品股份有限公司（以下简称"稳健医疗"或"公司"）董事 会的独立董事，在任职期间，严格按照《公司法》《证券法》《上市公司独立董 事管理办法》《上市公司治理准则》《深圳证券交易所上市公司自律监管指引第 2号——创业板上市公司规范运作》《公司章程》及《公司独立董事工作制度》 等法律法规、规范性文件的相关规定和要求，积极出席相关会议，忠实、勤勉地 履行了独立董事的职责，维护了公司和股东特别是中小股东的切身利益。现将本 人2024年度的履职情况汇报如下： 一、独立董事基本情况 本人彭剑锋，1961年出生，中国国籍，无境外永久居留权，中国人民大学硕 士学位。1986年至今，在中国人民大学劳动人事学院陆续担任讲师、副教授和教 授；此前，陆续担任天音通信控股股份有限公司、山河智能装备股份有限公司、 歌尔股份有限公司、中文天地出版传媒集团股份有限公司、海尔智家股份有限公 司、招商蛇口工业区控股股份有限公司和周大生珠宝股份有限公司独立董事；现 任海能达通信股份有限公司非独立董事、建信信托有限责任公司董事，以及担任 北京华夏基 ...

Financial Performance - The total cash dividend for 2024 amounted to ¥378,514,375.20 (including tax), representing 54.43% of the net profit attributable to ordinary shareholders[16]. - The company reported a significant growth in revenue, achieving a total of 1.2 billion CNY for the fiscal year 2024, representing a 15% increase year-over-year[24]. - The company's operating revenue for 2024 reached ¥8,977,853,631.73, representing a 9.69% increase compared to ¥8,185,022,057.20 in 2023[39]. - Net profit attributable to shareholders for 2024 was ¥695,378,928.72, a 19.81% increase from ¥580,403,232.37 in 2023[39]. - The net profit after deducting non-recurring gains and losses increased by 43.40% to ¥590,858,058.78 in 2024 from ¥412,027,497.25 in 2023[39]. - The net cash flow from operating activities for 2024 was ¥1,265,755,266.70, up 19.04% from ¥1,063,326,232.23 in 2023[39]. - Basic earnings per share for 2024 increased by 21.43% to ¥1.19 from ¥0.98 in 2023[39]. - The company's total revenue for 2024 reached ¥8,977,853,631.73, representing a year-on-year increase of 9.69% compared to ¥8,185,022,057.20 in 2023[134]. - The medical consumables segment generated ¥3,905,583,866.46, accounting for 43.50% of total revenue, with a slight increase of 1.14% from the previous year[134]. - The consumer products segment saw significant growth, with revenue of ¥4,990,886,442.62, which is 55.59% of total revenue, reflecting a year-on-year increase of 17.09%[134]. Market Expansion and Strategy - The company successfully acquired GRI in the United States, filling capacity gaps in the U.S., Vietnam, and the Dominican Republic, thereby optimizing the supply chain and expanding into international markets[6]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share in the region by 2025[24]. - The acquisition of GRI, which was completed in 2024, is expected to enhance the company's supply chain efficiency and add 300 million CNY in annual revenue[21]. - The company has made strategic acquisitions, including leading firms in niche markets, to enhance its product offerings in injection and puncture consumables, latex gloves, and more[100]. - The company is focused on building an international professional team, implementing a comprehensive talent development strategy to support its growth objectives[108]. Product Development and Innovation - The company achieved key progress in the bionic artificial cornea project in collaboration with universities, successfully conducting pilot tests for collagen extraction technology[5]. - The company has introduced advanced production equipment and processes to enhance production efficiency and reduce energy consumption and pollution[5]. - The company has invested 100 million CNY in R&D for new technologies in medical supplies, focusing on sustainable materials[24]. - The company is actively promoting smart and green manufacturing technologies to improve production efficiency and energy management[4]. - The company has successfully launched several new products, including a daily disposable sunscreen mask and a three-resistant cotton surgical gown, enhancing its product line and market competitiveness[178]. - The company is in the process of developing a bionic artificial cornea using type I collagen, aiming for a purity level exceeding 99%[178]. - The company has launched the fourth generation of its star product, silicone gel foam dressings, enhancing its market influence in the high-end wound care sector[126]. - The company has developed a long-lasting antibacterial cotton non-woven fabric for sanitary napkins, enhancing product differentiation and market competitiveness[176]. Consumer Engagement and Brand Development - User data indicates a 20% increase in active users for the Purcotton brand, reaching 5 million users by the end of 2024[24]. - The "Purcotton" brand has launched over ten new product categories, including cotton soft towels and sanitary napkins, and has established a sales network across more than 100 cities in China, leveraging both online and offline channels[2]. - The company has shifted its business model from OEM to self-owned brand development, expanding from B2B to B2C, and balancing domestic and international markets[3]. - The company emphasizes a dual-driven business model combining medical and consumer sectors, enhancing its resilience against economic fluctuations[103]. Social Responsibility and Sustainability - The company maintains a strong commitment to social responsibility, with initiatives aimed at reducing environmental impact by 15% over the next three years[34]. - The company is committed to creating a sustainable cotton lifestyle through its "Purcotton" brand, emphasizing comfort, health, and environmental friendliness[2]. - The company is committed to developing biodegradable materials for medical devices, aligning with market demands for environmentally friendly products[176]. Financial Challenges and Risks - The fourth quarter of 2024 saw a revenue increase but a profit decline, primarily due to a goodwill impairment loss of ¥90,740,000[41]. - The company reported a goodwill impairment of CNY 90.74 million for the acquisition of Weijian Guilin due to decreased market demand for its main products[122]. - The company reported a significant asset impairment loss of ¥242,895,761.34, representing -26.74% of total profits, mainly due to inventory write-downs, goodwill impairment, and fixed asset impairment provisions, which are not sustainable[186].

Financial Performance - The company's revenue for Q1 2025 reached ¥2,605,313,851.05, representing a year-over-year increase of 36.47%[4] - Net profit attributable to shareholders was ¥248,565,301.08, up 36.26% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses increased by 62.46% to ¥234,265,747.12, primarily due to a decrease in non-recurring gains and losses by 62.59%[4] - Cash received from sales of goods and services increased by 42.72% to ¥2,603,886,397.75, reflecting the growth in revenue[12] - The company achieved a total revenue of 2.61 billion yuan in Q1 2025, representing a year-over-year growth of 36.5%[19] - The net profit attributable to shareholders reached 250 million yuan, with a year-over-year increase of 36.3%, while the net profit excluding non-recurring items was 230 million yuan, up 62.5%[19] - Total operating revenue for the current period reached ¥2,603,886,397.75, an increase of 42.7% compared to ¥1,824,449,756.14 in the previous period[33] - Net profit attributable to the parent company was ¥248,565,301.08, up 36.3% from ¥182,424,811.95 year-over-year[31] - Total comprehensive income for the current period was ¥258,677,968.39, compared to ¥194,542,000.87 in the previous period, reflecting a growth of 32.9%[31] Cash Flow and Assets - The company's cash flow from operating activities showed a net outflow of ¥230,322,471.93, a decline of 40.90% year-over-year, mainly due to increased payments for accounts payable and taxes[4] - The company reported a net cash flow from operating activities of -¥230,322,471.93, worsening from -¥163,462,761.04 in the previous period[34] - Cash and cash equivalents at the end of the period were ¥1,217,526,685.94, down from ¥3,722,529,027.60 year-over-year[35] - Total assets at the end of the reporting period were ¥17,788,836,031.96, down 3.28% from the end of the previous year[4] - The company reported total assets of approximately 17.79 billion yuan as of March 31, 2025, down from 18.39 billion yuan at the beginning of the period[25][27] - The total liabilities decreased from approximately 6.52 billion yuan to 5.64 billion yuan during the same period[27] Segment Performance - The medical segment revenue grew by 46.3%, while the consumer goods segment revenue increased by 28.8%[4] - The medical segment generated 1.25 billion yuan in revenue, with a year-over-year growth of 46.3%, including 300 million yuan from the newly acquired company GRI[20] - Key product categories in the medical segment saw significant growth: surgical consumables at 370 million yuan (up 196.8%), high-end dressings at 220 million yuan (up 21.1%), and health personal care products at 120 million yuan (up 39.8%)[20] - In the consumer sector, the company reported operating revenue of 1.34 billion yuan, a year-on-year increase of 28.8%[21] - The sales revenue of the Princess Nais sanitary napkin reached 310 million yuan, growing 73.5% year-on-year, leading the development of the entire category[21] - The core categories of wet and dry cotton soft towels and adult clothing achieved operating revenues of 370 million yuan and 250 million yuan, with year-on-year growth rates of 38.6% and 23.4%, respectively[21] - E-commerce channels contributed 59.9% of the revenue for the consumer goods sector during the reporting period[21] Expenses and Investments - The company reported a significant increase in management expenses by 43.28% due to the contribution from newly acquired companies[11] - The company experienced a 68.74% decrease in investment income, primarily due to increased losses from associated enterprises[11] - Research and development expenses increased to ¥92,098,187.41, representing a rise of 21.1% from ¥75,999,859.76 in the previous period[30] - The company incurred a total tax expense of ¥72,532,819.09, which is an increase from ¥30,247,700.49 in the previous period[30] - The company’s total operating costs increased to ¥2,256,241,035.86, up 32.1% from ¥1,707,213,229.42 in the previous period[30] Shareholder Information - The total number of common shareholders at the end of the reporting period was 21,410[14] - The largest shareholder, Steady Group Limited, holds 69.83% of the shares, totaling 406,614,387 shares[14] - The company has a commitment to extend the lock-up period for its controlling shareholder's shares until September 16, 2025[18] Strategic Focus - The company maintains a strong focus on quality over profit, brand over speed, and social value over corporate value as part of its core operational principles[19] - The company emphasizes a strategy of product leadership, excellent operations, and a global perspective for sustainable growth[19] - The company plans to enhance its brand image through innovative green technology and active participation in social responsibility initiatives[22] - The company is focusing on product development and market expansion, particularly in strategic categories, to improve its industry ranking[23] Growth Channels - The company’s foreign sales channels continue to grow rapidly, contributing to overall revenue growth[20] - The company achieved operating revenue of 700 million yuan, representing a year-on-year growth of 84.1%, with C-end business (domestic pharmacies and e-commerce channels) growing over 40%[21] - Investment activities generated a net cash flow of ¥559,585,668.05, a significant improvement from -¥309,795,884.33 in the previous period[34] - Basic and diluted earnings per share were both ¥0.43, an increase from ¥0.31 in the previous period[31]

Core Insights - The stock of Steady Medical closed at 48.68 yuan, up 6.06%, with a latest price-to-book ratio of 2.49, marking a new low in 460 days, and a total market capitalization of 28.348 billion yuan [1] - As of the Q3 2024 report, 55 institutions hold shares in Steady Medical, with a total of 19.4574 million shares valued at 896 million yuan [1] - Steady Medical specializes in the research, production, and sales of cotton-based products across various sectors, including medical, personal care, and home care [1] Financial Performance - For Q3 2024, the company reported revenue of 6.07 billion yuan, a year-on-year increase of 0.99%, and a net profit of 553 million yuan, reflecting a year-on-year decrease of 74.25%, with a gross profit margin of 48.14% [1] Market Position - Steady Medical has consistently ranked among the top three exporters of medical dressings in China for several years, with its "winner" brand products available in over 2,000 hospitals and nearly 40,000 pharmacies across the country [1] - The "winner" brand has also achieved coverage in all public hospitals and most private hospitals in Hong Kong [1] Valuation Metrics - The company has a trailing twelve months (TTM) price-to-earnings (PE) ratio of -27.95 and a static PE ratio of 48.84, with a market capitalization of 28.348 billion yuan [2] - The industry average PE TTM is 48.92, while the industry median is 39.80 [2]

4月21日，稳健医疗今日收盘46.02元，上涨5.79%，最新市净率2.36，创15天以来新低，总市值267.99亿 元。 资金流向方面，4月21日，稳健医疗主力资金净流入358.77万元，近5日总体呈流入状态，5日共流入 137.02万元。 稳健医疗用品股份有限公司主要从事棉类制品的研发、生产、销售，覆盖医疗卫生、个人护理、家庭护 理、母婴护理、家纺服饰等多领域的企业。公司主要产品包括高端伤口敷料产品、传统伤口护理与包扎 产品、手术室感染控制产品、疾控防护产品、体表清理消毒清洁产品、纯棉柔巾、全棉表层卫生巾、纯 棉湿巾、婴童用品、婴童服饰、成人服饰等。根据中国医保商会统计的数据,公司已连续多年稳居中国 医用敷料出口前三名。公司自主"winner"品牌已进入国内两千多家医院和近四万家药店,其中大多数医院 为三级医院,并在海王星辰、老百姓大药房等多家知名连锁药店设有公司产品专柜;在中国香港地 区"winner"品牌产品已覆盖全港全部公立和大部分私立医院。 最新一期业绩显示，2024年三季报，公司实现营业收入60.70亿元，同比0.99%；净利润5.53亿元，同 比-74.25%，销售毛利率48.14%。 序号股 ...

Investment Rating - The report suggests a positive outlook for the apparel sector, indicating potential investment opportunities as consumer confidence and spending gradually recover [1][10]. Core Insights - In March, retail sales showed a robust performance with a year-on-year growth of 5.9%, while apparel retail sales grew by 3.6%, slightly below the overall market due to adverse weather conditions affecting spring apparel sales [1][10]. - The report highlights that the recovery in consumer spending is supported by government initiatives, including consumption subsidies and a special action plan to boost consumption [1][10]. - The apparel sector is viewed as being in a recovery phase, with potential for further growth as temperatures rise in key cities, which is expected to enhance sales of spring and summer clothing [1][10]. Industry Data Tracking - Raw material prices remain stable, with 328 grade cotton priced at 14,902 RMB per ton, and the price of American cotton at 80.1 cents per pound [3][14]. - The report tracks various segments within the industry, noting that the sports and outdoor apparel sector is on an upward trend, while men's and women's apparel are stabilizing at the bottom [3][14]. Investment Recommendations - For apparel brands, the report recommends companies like Hailan Home, which is adapting to consumer trends and has strong profitability potential, and Anta Sports, which is expected to benefit from the recovery of major brands like Adidas and Nike [4][26]. - In the upstream manufacturing sector, the report suggests that leading textile manufacturers are well-positioned to withstand external uncertainties, with recommendations for companies such as Zhejiang Natural and Shenzhou International [4][26]. Market Review and Company Announcements - The textile and apparel sector saw a weekly increase of 1.57%, ranking 6th among 28 industry sectors [5][21]. - Key company announcements include Baolong Oriental reporting a revenue of 7.941 billion RMB, a year-on-year increase of 14.86%, despite a decline in net profit [5][31].

Core Viewpoint - The company,稳健医疗, is experiencing a decline in stock price and profitability, with a significant drop in net profit despite a slight increase in revenue, indicating potential challenges in maintaining growth and profitability in the competitive medical supplies market [1][2]. Company Overview - The company specializes in the research, production, and sales of cotton-based products across various sectors, including medical, personal care, and home care [1]. - Key products include advanced wound dressings, traditional wound care products, infection control products, and a range of personal hygiene items [1]. - The company has consistently ranked among the top three exporters of medical dressings in China and has established a strong presence in domestic hospitals and pharmacies [1]. Financial Performance - For the third quarter of 2024, the company reported a revenue of 6.07 billion yuan, reflecting a year-on-year increase of 0.99% [1]. - Net profit for the same period was 553 million yuan, showing a significant decline of 74.25% year-on-year [1]. - The gross profit margin stood at 48.14%, indicating the company's ability to maintain a healthy margin despite the drop in net profit [1]. Shareholder Information - As of September 30, 2024, the company had 28,966 shareholders, a decrease of 201 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]. Market Valuation - The company's latest closing price was 43.5 yuan, with a market-to-book ratio of 2.23 and a total market capitalization of 25.331 billion yuan [1][2]. - The company's price-to-earnings ratio (TTM) is reported at -24.97, indicating negative earnings relative to its stock price [2].

它会看到正面红色 从这个举起的板块来看,三年整个用耗材的业务是39亿,大概占比47%,消费品板块是43亿,占比52%从目前来看基本上是无物财这样的一个占比,但是消费品板块这个业务占比有一个提升的趋势从具体的参照来看,首先是用耗材板块 像刀刃伤口不亮 请看前面的视频 公司的一个增长信心主要来自于哪里就我们觉得现在最主要的还是来自于它的这个消费型板块那首先这个消费型板块在20年其实是来到了营收期数的一个关键那从数据上来看20年这个1亿6相对平均增加7%把它记录增加14%把3亿6增加20%其实是一个非常明显的向好的趋势那这个数据爆发的来源也是因为20年 整理&字幕由Amara.org社区提供 高度品质大家知道就是一个年轻比较高的产品,所以说会员力的增长也可以理解为他公司显得活跃,包括中式用户的一个提升。那天下方面的话,同时续持保持着一个稳健的产品接受和发展的影响力,而那每年数量从去年247家提升到444家。 提一下我们刚刚外发的稳定医疗程度报告。稳定医疗相对来说,它对整个经济环境没有那么敏感,跟我们另外两个推荐的公司,包括海南之家和淘宝比较相似。按那些名来,我就详细介绍一下这个报告。 首先是我们针对公司主要的产品 ...

Summary of Conference Call Companies Involved - **Wanjian Medical (稳健医疗)** - **Baiya Co., Ltd. (百亚股份)** Key Points and Arguments Response to Pandemic Incident - Both companies received inquiries from the Shenzhen Stock Exchange regarding the pandemic incident and responded positively, clarifying that they had no knowledge of the reported violations involving the waste recycling company Liangshan CC and had no transactions with them [1] Internal Control on Raw Material Procurement - Wanjian Medical stated that its internal management process for raw material procurement is very strict, ensuring that core raw materials come from top suppliers and are only used after passing quality checks [2] - Baiya Co., Ltd. also emphasized its comprehensive management system for procurement, including supplier evaluation and real-time inspection of raw materials before production [2] Handling of Silk Waste - Wanjian Medical confirmed that the handling of silk waste is compliant, with professional recycling companies managing the process [3] - Baiya Co., Ltd. mentioned that waste materials are categorized and processed by qualified recycling entities, ensuring safety and compliance [3] Improvement in Waste Management Practices - Both companies have decided to take full control of the disposal of waste materials, including self-managed destruction methods to prevent any potential misuse of waste as raw materials [4] - They are enhancing employee training on internal control awareness and operational processes [4] Market Outlook and Consumer Trends - Since Q4 of the previous year, there has been increased consumer concern regarding the safety of sanitary products, leading to a potential increase in market concentration among leading brands [5] - Smaller brands may face pressure as consumer focus shifts towards established brands with better safety records [5] Impact of Sales Channels - Official sales channels have shown 100% compliance in hygiene testing, reducing the risk of counterfeit products [6] - The presence of low-cost counterfeit products in unofficial channels may negatively impact brand perception, but official channels are expected to mitigate this effect [6] Brand Positioning and Market Share - Brands like Nice Princess and Quanmin Shida, backed by Wanjian Medical, are expected to regain market share as the impact of recent controversies stabilizes [7] - The companies are focusing on enhancing their product offerings in the health sector, which is crucial for brand recognition and market expansion [7] Long-term Brand Development - The companies believe that the recent challenges have strengthened their management capabilities and will not adversely affect their long-term brand image [8] - As the market stabilizes, both companies anticipate a return to growth in sales and market presence [8] Additional Important Content - The companies are committed to improving consumer trust and ensuring the safety of their products through enhanced internal controls and waste management practices [4][5][8]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of the company, Steady Medical, which has seen a decline in net profit despite stable revenue growth [1][2] - As of the latest report, Steady Medical's stock closed at 42.4 yuan, down 1.42%, with a market-to-book ratio of 2.17 and a total market capitalization of 24.691 billion yuan [1] - The company has 366 institutional holders, with 365 being funds and 1 brokerage, holding a total of 54.1236 million shares valued at 2.278 billion yuan [1] Group 2 - Steady Medical specializes in the research, production, and sales of cotton-based products across various sectors, including medical, personal care, and home care [1] - The company's main products include high-end wound dressings, traditional wound care products, infection control products, and various cotton-based personal care items [1] - According to statistics from the China Medical Insurance Association, the company has consistently ranked among the top three exporters of medical dressings in China [1] Group 3 - For the third quarter of 2024, Steady Medical reported a revenue of 6.07 billion yuan, a year-on-year increase of 0.99%, while net profit was 553 million yuan, reflecting a significant decline of 74.25% [1] - The sales gross margin for the company stood at 48.14% [1] - The company's "winner" brand has penetrated over 2,000 hospitals and nearly 40,000 pharmacies in China, with a strong presence in major chains [1]